An experimental animal model for the demyelinating disease of GUILLAINE-BARRE SYNDROME. In the most frequently used protocol, animals are injected with a peripheral nerve tissue protein homogenate. After approximately 2 weeks the animals develop a neuropathy secondary to a T cell-mediated autoimmune response directed towards the MYELIN P2 PROTEIN in peripheral nerves. Pathologic findings include a perivascular accumulation of macrophages and T lymphocytes in the peripheral nervous system, similar to that seen in the Guillaine-Barre syndrome. (From Adams et al., Principles of Neurology, 6th ed, p1314; J Neuroimmunol 1998 Apr 1;84(1):40-52)
Also Known As:
Neuritis, Autoimmune, Experimental; EAN (Experimental Allergic Neuritis); EAN (Experimental Autoimmune Neuritis); Experimental Allergic Neuritis; Experimental Autoimmune Neuropathy; Neuritis, Experimental Autoimmune; Autoimmune Neuropathies, Experimental; Autoimmune Neuropathy, Experimental; Experimental Autoimmune Neuropathies; Neuropathies, Experimental Autoimmune; Neuropathy, Experimental Autoimmune; Allergic Neuritis, Experimental; Autoimmune Neuritis, Experimental; Neuritis, Experimental Allergic